Ovarian Disorders
Methodology & AI Transparency ⓘ
Ovarian Disorders Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What are ovaries? The ovaries are a pair of female reproductive glands that make eggs and female hormones .
- 2 Real-world patient consensus: Federal ICD-10-CM code N80.4 categorizes Ovarian Disorders under PCOS, Endometriosis & Gynecologic Health.
- 3 Typical cash cost range: Workup highlights for Ovarian Disorders (N80.4): iron repletion [Ovarian Disorders N80.4].
- 4 Top reported side effects / signs: Objective lab/clinical target for Ovarian Disorders: Free & Total in Ovarian Disorders (N80.4: Testosterone + SHBG) (Sex-specific physiological range (N80.4)) and Fasting Insulin & in Ovarian Disorders (N80.4: HbA1c).
Ask our AI Specialists anything about Ovarian Disorders
What Is Ovarian Disorders?
What are ovaries? The ovaries are a pair of female reproductive glands that make eggs and female hormones . Women have one ovary on each side of the uterus (where a fetus grows during pregnancy). Each ovary is about the size and shape of an almond. Ovaries play a role in menstruation , pregnancy, and menopause . Your ovaries: Produce and store eggs that are released during ovulation (when an egg leaves the ovary and travels into the fallopian tube). If a sperm fertilizes the egg, you can become pregnant. Make the female hormones estrogen and progesterone. Stop making those hormones and releasing eggs during menopause. Some medical problems can affect the ovaries.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in ob/gyn & pcos, Ovarian Disorders (N80.4) involves reduced hepatic SHBG in Ovarian Disorders (N80.4: (in PCOS)). Cross-referenced with NIH MeSH (Ovarian Diseases), progression correlates with shifts in Free & Total in Ovarian Disorders (N80.4: Testosterone + SHBG) (Sex-specific physiological range (N80.4)).
Common Symptoms & Clinical Signs
- • Make the female hormones estrogen and progesterone
- • Stop making those hormones and releasing eggs during menopause
- • Presentation of Ovarian Disorders (N80.4): irregular, infrequent, or in Ovarian Disorders (N80.4: absent ovulatory menstrual)
- • Secondary Ovarian Disorders clinical sign: severe pelvic cramping [Ovarian Disorders N80.4]
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Ovarian Disorders Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N80.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | PCOS, Endometriosis & Gynecologic Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Free & Total in Ovarian Disorders (N80.4: Testosterone + SHBG) | Sex-specific physiological range (N80.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Insulin & in Ovarian Disorders (N80.4: HbA1c) | Fasting insulin < 8 uIU/mL (N80.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CBC & Serum in Ovarian Disorders (N80.4: Ferritin (heavy bleeding)) | Ferritin > 50 ng/mL (N80.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Ovarian Disorders
Treatment selection for Ovarian Disorders depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ovarian Disorders)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Veliparib concomitant with first-line chemotherapy and as maintenance therapy in: What a 1,140-Participant Study Found No OS or DRS benefit of addition of veliparib to platinum-based chemotherapy and continued as maintenance therapy was detected in this study, despite an observed. European journal of cancer (Oxford, England : 1990) • 2025-07-25 • Phase III Randomized Trial | N = 1,140 | 96/100 | PMID 40561681 ↗ |
| New Insights on Impact of subclinical hypothyroidism on core reproductive hormones and ovarian: What a 3,114-Participant Study Found Current evidence shows no significant differences in FSH, LH, estradiol, or total testosterone levels between SCH and euthyroid PCOS controls, while the evidence for prolactin. Frontiers in endocrinology • 2026-01-15 • Meta-Analysis | N = 3,114 | 94/100 | PMID 42798498 ↗ |
| New Insights on Reproductive hormone characteristics of obese Chinese patients with polycystic: What a 4,554-Participant Study Found Conversely, they exhibited significantly higher testosterone (T) ( p = 0.001) levels. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology • 2025-12-15 • Meta-Analysis | N = 4,554 | 94/100 | PMID 40287875 ↗ |
| New Insights on Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women: What a 1,157-Participant Study Found Maintenance therapy with P and PP did not improve OS among patients with newly diagnosed O/tubal/peritoneal cancer, but may modestly increase PFS. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2022-12-10 • Phase III Randomized Trial | N = 1,157 | 90/100 | PMID 35759733 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of intravenous administration of high-dose selenium for Intravenous high-dose selenium safely failed to reduce grade 1 or more CIPN, whereas it reduced grade 2 or more motor dysfunction during chemotherapy in patients with PSROC, especially those ≥ 60 years. BMC medicine • 2026-02-02 • Phase III Randomized Trial | N = 68 | 88/100 | PMID 41630017 ↗ |
Ovarian Disorders Patient Community & “People Like Me” Threads
Filter Ovarian Disorders community threads and patient logs by age, biological sex, dosage, and treatment duration.